Report Details:
15 Companies Covered
150 Pages
Market Highlights
The Global Oral Anticoagulants Market Size was estimated at 24.76 USD Billion in 2024. The oral anticoagulants industry is projected to grow from 26.13 USD Billion in 2025 to 44.77 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.53% during the forecast period 2025-2035.
Anticoagulant is a drug, when added to blood, prevents it from clotting. Anticoagulants achieve their effect by suppressing the synthesis or function of various clotting factors that are normally present in the blood. Such drugs are often used to prevent the formation of blood clots (thrombi) in the veins or arteries or the enlargement of a clot that is circulating in the bloodstream.
Increasing cardiovascular disorders, rising geriatric population, and increasing surgical procedures support the growth of the global oral anticoagulants market in recent years. However, the high cost is likely to restrain market growth over the forecast period.
Key Players
Market Research Future (MRFR) recognizes the following companies as the key players in the global oral anticoagulants market that includes AstraZeneca, Plc (UK), Pfizer (US), Boehringer Ingelheim GmbH (Germany), Daiichi Sankyo Company Ltd (Japan), Abbott Laboratories (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK) Portola Pharmaceuticals Inc. (US), Medicure (Canada), Johnson & Johnson Services Inc. (US), and others.
Segment Analysis
The global oral anticoagulants market has been segmented into product, disease indication, distribution channel, and region. Based on product, the oral anticoagulants market has been segmented into novel oral anticoagulant and warfarin.
On the basis of disease indication, the global oral anticoagulants market has been segmented into atrial fibrillation (AF)/ stroke prevention and deep vein thrombosis/ pulmonary embolism, and others. On the basis of distribution channel, the global oral anticoagulants market has been segmented into hospital pharmacies, retail pharmacies, and E-commerce.
Regional Analysis
Geographically, the Americas is expected to dominate the global oral anticoagulants market. This is owing to increasing cardiovascular disorders and increasing surgical procedures. Europe showed a considerable amount of growth in the market due to the rising geriatric population. Asia-Pacific is estimated to be the fastest growing region in the market. This is owing to increasing cardiovascular disorders and rising geriatric population. On the other hand, the Middle East & Africa has the least share of the market.
Key Findings of the Study:
- The demand for novel anticoagulants is rising, particularly in North America, which remains the largest market.
- The Asia-Pacific region is emerging as the fastest-growing market, fueled by advancements in healthcare infrastructure.
- Novel oral anticoagulants dominate the market, while warfarin is witnessing rapid growth due to its established use in various conditions.
- Key market drivers include the increasing prevalence of cardiovascular diseases and advancements in drug development, which are shaping the future of anticoagulant therapies.
This research report provides the insights, on various levels of analyses such as industry analysis, market share analysis leading market players and their profiles. This report also helps in studying the target segments by providing views on emerging & high-growth segments and market conclusion. Together the market data comprise and discuss with the basic assessments on the competitive scenarios & strategies, of the Global Oral Anticoagulants Market, including the high-growth regions and their political, economic and technological environments. Furthermore, the project report also provides the views over the historical market values as well as, pricing and cost analysis of the same.
